Vos, Niels
Haghshenas, Sadegheh
van der Laan, Liselot
Russel, Perle K. M.
Rooney, Kathleen
Levy, Michael A.
Relator, Raissa
Kerkhof, Jennifer
McConkey, Haley
Maas, Saskia M.
Vissers, Lisenka E. L. M.
de Vries, Bert B. A.
Pfundt, Rolph
Elting, Mariet W.
van Hagen, Johanna M.
Verbeek, Nienke E.
Jongmans, Marjolijn C. J.
Lakeman, Phillis
Rumping, Lynne
Bosch, Danielle G. M.
Vitobello, Antonio
Thauvin-Robinet, Christel
Faivre, Laurence
Nambot, Sophie
Garde, Aurore
Willems, Marjolaine
Genevieve, David
Nicolas, Gaël
Busa, Tiffany
Toutain, Annick
Gérard, Marion
Bizaoui, Varoona
Isidor, Bertrand
Merla, Giuseppe
Accadia, Maria
Schwartz, Charles E.
Ounap, Katrin
Hoffer, Mariëtte J. V.
Nezarati, Marjan M.
van den Boogaard, Marie-José H.
Tedder, Matthew L.
Rogers, Curtis
Brusco, Alfredo
Ferrero, Giovanni B.
Spodenkiewicz, Marta
Sidlow, Richard
Mussa, Alessandro
Trajkova, Slavica
McCann, Emma
Mroczkowski, Henry J.
Jansen, Sandra
Donker-Kaat, Laura
Duijkers, Floor A. M.
Stuurman, Kyra E.
Mannens, Marcel M. A. M.
Alders, Mariëlle
Henneman, Peter
White, Susan M.
Sadikovic, Bekim
van Haelst, Mieke M.
Funding for this research was provided by:
Genome Canada (OGI-188)
Article History
Received: 14 December 2023
Accepted: 9 May 2024
First Online: 24 May 2024
Declarations
:
: B.S. is a shareholder in EpiSign Inc, company involved in commercialization of EpiSign™ technology.